Monoclonal antibody
Identifiers |
---|
CAS Number | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
Chemical and physical data |
---|
Formula | C6338H9790N1694O1988S42 |
---|
Molar mass | 142874.43 g·mol−1 |
Landogrozumab (INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.[1][2]
The drug was developed by Eli Lilly and Company.
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Landogrozumab, American Medical Association.
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).